Delivery Order SPE2DB25D3012-SPE2DB26FWVXK
- Not listed
- The Defense Logistics Agency awarded a $2,601.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for FORTEO (Fortified Growth Factor) 560 MCG/2.24 ML pen injections on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement to support federal medical supply needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $11,404.44 to AmerisourceBergen Drug Corp for the supply of FORTEO 560 MCG/2.24 ML pen injections on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,363.00 to AmerisourceBergen Drug Corp for FORTEO 560 mcg/2.24 ml pen injections. This order, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed price delivery under a competitive, non-set-aside procurement. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $14,640.18 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections) on April 24, 2025, with completion scheduled for April 25, 2025. This competitive award utilizes firm fixed pricing and is performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,748.30 to AmerisourceBergen Drug Corp for FORTEO 560 micrograms per 2.24 milliliter pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of October 27, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injection) with a ceiling value of $8,274.44. The contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and serve as the prime contractor for this...
- The Defense Logistics Agency awarded a $12,869.67 delivery order to AmerisourceBergen Drug Corp for FORTEO (560 mcg/2.24 mL pen injections), a brand-name pharmaceutical product used in osteoporosis treatment. The contract is a firm fixed-price delivery order with an ultimate completion date of May 19, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,220.43 for FORTEO 560 mcg/2.24 mL pen injections on June 3, 2025, with completion targeted for June 4, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio. The product will be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,601.43 to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections on July 21, 2025, with completion targeted for July 22, 2025. This firm fixed price contract, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for FORTEO (teriparatide) 560 mcg/2.24 mL pen injections valued at $7,529.58. The award was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a firm fixed price transaction with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office as a primary...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB26FWVXKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for FORTEO 560 MCG/2.24 ML pen injections valued at $6,024.75, with an ultimate completion date of November 12, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor for medical supply procurement supporting federal healthcare needs. The contract was performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime contract vehicle running through December 2026. The parent IDC enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's extensive federal contract portfolio demonstrates consistent capability to fulfill open competition requirements across diverse therapeutic domains, positioning it as a critical vendor within the DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 11/10/25 |